Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Short-term Investments (2021 - 2025)

Zymeworks' Short-term Investments history spans 3 years, with the latest figure at $201.1 million for Q3 2023.

  • For Q3 2023, Short-term Investments rose 186.59% year-over-year to $201.1 million; the TTM value through Sep 2023 reached $201.1 million, up 186.59%, while the annual FY2022 figure was $91.3 million, 79.97% up from the prior year.
  • Short-term Investments for Q3 2023 was $201.1 million at Zymeworks, up from $198.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $201.1 million in Q3 2023 and bottomed at $50.7 million in Q4 2021.
  • The 3-year median for Short-term Investments is $125.3 million (2022), against an average of $128.4 million.
  • The largest annual shift saw Short-term Investments surged 79.97% in 2022 before it surged 186.59% in 2023.
  • A 3-year view of Short-term Investments shows it stood at $50.7 million in 2021, then skyrocketed by 79.97% to $91.3 million in 2022, then soared by 120.19% to $201.1 million in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Short-term Investments are $201.1 million (Q3 2023), $198.0 million (Q2 2023), and $159.2 million (Q1 2023).